Substance / Medication

Darifenacin

Overview

Active Ingredient

darifenacin

RxNorm CUI

136198

Indications

® ENABLEX(darifenacin) extended-release tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.

Labeler: Physicians Total Care, Inc.Updated: 2010-01-01T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

® ENABLEX(darifenacin)extended-release tabletsare contraindicated in patients with urinary retention, gastric retention or uncontrolled narrow-angle glaucoma and in patients who are at risk for these conditions. ENABLEX is also contraindicated in patients with known hypersensitivity to the drug o

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Instability of bladder

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data.

Kerbusch Thomas, Milligan Peter A, Karlsson Mats O · Br J Clin Pharmacol · 2004

PMID: 14748816Meta-AnalysisFull text (PMC)

Neurological safety and efficacy of darifenacin and mirabegron for the treatment of overactive bladder in patients with history of cerebrovascular accident: A prospective study.

Vasudeva Pawan, Kumar Amitabh, Yadav Siddharth et al. · Neurourol Urodyn · 2021

PMID: 34516666RCT

Evaluation of the efficacy of solifenacin and darifenacin for prevention of catheter-related bladder discomfort: a prospective, randomized, placebo-controlled, double-blind study.

Srivastava Vinit K, Nigam Rakesh, Agrawal Sanjay et al. · Minerva Anestesiol · 2016

PMID: 27607187RCT

Time-to-effect with darifenacin in overactive bladder: a pooled analysis.

Khullar Vik, Foote Jenelle, Seifu Yodit et al. · Int Urogynecol J · 2011

PMID: 22006023RCT

QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder.

Serra Denise B, Affrime Melton B, Bedigian Martin P et al. · J Clin Pharmacol · 2005

PMID: 16100298RCT

Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder.

Zinner Norman, Tuttle John, Marks Leonard · World J Urol · 2005

PMID: 16096831RCT

Effect of darifenacin on fecal incontinence in women with double incontinence.

Kissane Lindsay M, Martin Kimberly D, Meyer Isuzu et al. · Int Urogynecol J · 2021

PMID: 32542466ObservationalFull text (PMC)

The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function.

Golding John F, Wesnes Keith A, Leaker Brian R · Br J Clin Pharmacol · 2018

PMID: 29522648ObservationalFull text (PMC)

Validated liquid chromatographic-fluorescence method for the quantitation of darifenacin in mice plasma and its application to a pharmacokinetic study.

Hefnawy M M, Alanazi A M, Abounassif M A et al. · Talanta · 2014

PMID: 24607107Observational

Comparison of two selective muscarinic receptor antagonists (solifenacin and darifenacin) in women with overactive bladder--the SOLIDAR study.

But Igor, Goldstajn Marina Sprem, Oresković Slavko · Coll Antropol · 2012

PMID: 23390832Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Darifenacin (substance)
SNOMED CT: 416140008
UMLS CUI: C0529351
RxNorm CUI: 136198
Labeler: Physicians Total Care, Inc.

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.